Situated in Beverly, Massachusetts, Akston Biosciences utilizes its fundamental proficiency in creating innovative amalgamated proteins to produce and fabricate novel categories of biological treatments for Type 1 diabetes (T1D) prevention, extended-acting insulin therapy, and vaccines. Established by the team responsible for pioneering the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (acquired by Merck & Co. in 2010), Akston has secured more than $18 million in equity funding from the management team and private investors, in addition to $10 million from National Institutes of Health grants and The Helmsley Charitable Trust.